Effiskin(r), a veterinary hygiene product adapted to dogs with pyoderma prone skins

Posted by AlphanososResponsive · Innovative Products and Technologies · France

Summary of the technology

We are looking for distributors and/or licensees for Effiskin(r). This hygiene product is a lotion formulated around our patent pending alternative to antibiotics and chlorhexidine, a WECMEP (Water Extracts of Complex Mixes of Edible Plants) with a great safety profile. Successful animal model results and user testimony are available. Available as bulk formulation or finished product (spray), also for rebranding.


Current development status

Commercially available technology, sales started in France and Switzerland

Desired business relationship

Provider of bulk formulation and/or finished product with our without rebranding.

Patent licensing.

Intellectual property status

Patent already applied for

Patent application number: WO2018083115

Where: Worldwide

Technology Owner


Small and Medium Enterprise

Additional information (attached documents)

Related keywords

  • Soaps, detergents
  • Care, Hygiene, Beauty, Cosmetics
  • Environmental Medicine, Social Medicine, Sports Medicine
  • Virus, Virology / Antibiotics / Bacteriology
  • Veterinary Medicine
  • Medical Health related
  • Environmental Medicine, Social Medicine,Sports Medicine
  • Plant and animal health
  • Animal health
  • Consumer related
  • Consumer Products
  • Health and beautty aids, Cosmetics
  • veterinary
  • hygiene

About Alphanosos

Small and Medium Enterprise from France

Alphanosos is a privately held company incorporated in November 2014 in France. We are leveraging our disruptive, AI-based, proprietary discovery process to discover and patent active ingredients and products based on plants with a history of safe human consumption to replace, with superior efficacy and reduced risks of side effects, many of the chemical products used as therapeutic drugs in the human and animal health industries. We concentrate our discovery efforts on the selective killing of deleterious micro-organisms and cells. Our initial focus is on new antibiotics and anti-cancer products, with first products already in the post-discovery phase and a first patent application on anti-staphylococci products, for which we already obtained topical and systemic animal model results. Early revenue is already generated by licenses for cosmetic usage of certain of these products, to be soon followed with licenses for veterinary applications and later for human drugs.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.